What is Zenotech Laboratories Ltd (532039) share price return in the past 10 years?

Zenotech Laboratories Ltd share price has appreciated 0.8% annually (CAGR) over the past ten years.

What is the share price of Zenotech Laboratories Ltd (532039)?

Company share prices are keep on changing according to the market conditions. The current trading price of Zenotech Laboratories Ltd (532039) on 04-Jun-2026 16:59:59 at 16:59 is 45.00.

What is the P/E ratio of Zenotech Laboratories?

The latest standalone P/E ratio of Zenotech Laboratories as of 04-Jun-2026 is 0.00.

What is the P/B ratio of Zenotech Laboratories Ltd (532039)?

The latest standalone P/B ratio of Zenotech Laboratories Ltd (532039) as of 04-Jun-2026 is 2.89.

What is the 52-week high and low of Zenotech Laboratories Ltd (532039)?

The 52-week high of Zenotech Laboratories Ltd (532039) is Rs. 67.00 and the 52-week low is Rs. 33.55.

Zenotech Laboratories Ltd (532039) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Zenotech Laboratories Ltd (532039)
Brand: Zenotech Laboratories

Zenotech Laboratories Ltd (532039)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532039 NSE: Pharmaceuticals & Drugs | Small Cap | Zenotech Laboratorie Share Price

Zenotech Laboratories Ltd (532039)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532039 NSE: Pharmaceuticals & Drugs | Small Cap | Zenotech Laboratorie Share Price

Key Metrics

Valuation Multiples

Market Cap

₹275 Cr.

Current Price

₹45

52-Week Low / High

₹34 / 67

TTM EPS

₹-0.2

TTM Sales

₹39.6 Cr.

Book Value per Share

₹15.6

P/E Ratio

0.00

Lower than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

2.89

Lower than its 5-year historical median

Price to Sales (P/S)

6.94

Lower than its 5-year historical median

EV/EBITDA

21.24

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

6.01%

Underperforms industry median

Return on Capital Employed (ROCE)

11.46%

In line with industry median

Return on Assets (ROA)

5.43%

Operating Profit Margin

33%

Net Profit Margin

13.04%

Gross Profit Margin

36.5%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

5.44%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-17.65%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-32.41%

Asset Quality

Promoter Holding

68.84%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹34 Cr.

Equity

₹61 Cr.

Face Value

₹10

All Time Low / High

₹3.99 / 173.59

Zenotech Laboratories stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Zenotech Laboratories Ltd a good quality company?

Zenotech Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Zenotech Laboratories Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Zenotech Laboratories Ltd vs industry peers?

Zenotech Laboratories Ltd revenue CAGR is 10.59%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Zenotech Laboratories Ltd?

Promoters hold 68.84% of the Zenotech Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Zenotech Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 2.1% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-65.7%	0%	-61.9%	-6%	18.3%	0.5%	15.3%	18.4%	12.9%	11.5%	-
Value Creation Index ⓘ	NA	NA	-5.4	-1.4	0.3	-1.0	0.1	0.3	-0.1	-0.2	-
Growth Parameters ⓘ
Sales ⓘ	2.1	2.3	11.1	13	26	22.5	36.6	42.4	40.8	43.1	40
Sales YoY Gr.	-	9.2%	395.1%	17%	99.7%	-13.7%	62.9%	16%	-3.8%	5.4%	-
Adj EPS ⓘ	-5.2	-5.8	-1.9	-0.5	1	-0.2	3.6	1.9	1.4	0.7	-0.2
YoY Gr.	-	NA	NA	NA	NA	-119.2%	NA	-47.9%	-28%	-48.5%	-
BVPS (₹) ⓘ	-12.7	-18.2	6.9	6.4	8.1	7.9	11.6	13.5	14.8	15.8	15.6
Adj Net Profit ⓘ	-18.9	-21.1	-11.8	-3	6.3	-1.2	22.2	11.6	8.3	4.3	-1
Cash Flow from Ops. ⓘ	-4.8	1.6	-16.3	-14	11.4	5.7	17.7	20.7	11.8	9.5	-
Debt/CF from Ops. ⓘ	-11.3	33.2	0	-1.4	1.6	3.6	0.3	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	40.2%	10.6%	5.6%	5.4%
Adj EPS ⓘ	NA	-7.6%	-42.2%	-48.5%
BVPSⓘ	NA	14.1%	10.8%	6.1%
Share Price	0.8%	0.6%	-5.4%	-26.1%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	51.6	37.7	99.2	-7.5	14.3	-2.5	37.3	15.1	9.6	4.6	-1.2
Op. Profit Mgn % ⓘ	-372.5	-460.4	-70.5	-26	34.5	28.4	47.8	48.8	42.3	33	23.2
Net Profit Mgn % ⓘ	-917.4	-937.4	-106.3	-23.3	24.3	-5.4	60.7	27.3	20.4	9.9	-2.8
Debt to Equity ⓘ	-1.2	-0.8	0	0.5	0.4	0.4	0.1	0	0	0	0
Working Cap Days ⓘ	842	610	148	239	125	111	76	78	100	120	188
Cash Conv. Cycle ⓘ	252	106	-70	-42	-44	-9	9	-6	-10	17	131

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	2	2	11	13	26	22	37	42	41	43
Operating Expenses ⓘ +	10	13	19	17	17	16	19	22	24	29
Manufacturing Costs	2	5	9	8	9	8	10	11	11	12
Material Costs	2	2	1	1	1	0	0	0	0	1
Employee Cost	2	3	5	5	6	6	7	8	9	12
Other Costs ⓘ	4	3	4	3	2	2	2	2	3	3
Operating Profit ⓘ	-8	-10	-8	-4	9	6	17	21	17	14
Operating Profit Margin (%)	-389.0%	-461.0%	-70.6%	-27.0%	34.5%	28.4%	47.8%	48.8%	42.2%	32.9%
Other Income ⓘ +	0	0	2	5	1	0	1	1	1	2
Exceptional Items ⓘ	0	2	0	0	6	0	0	0	0	2
Interest ⓘ	8	8	2	0	1	2	1	0	0	0
Depreciation ⓘ	4	4	4	4	5	6	7	7	7	7
Profit Before Tax ⓘ	-19	-20	-12	-3	11	-1	10	15	11	11
Tax ⓘ	0	0	0	0	0	0	-12	3	3	5
Profit After Tax	-19	-20	-12	-3	11	-1	22	12	8	6
PAT Margin (%)	-929.0%	-881.0%	-106.0%	-24.0%	41.4%	-5.4%	60.7%	27.3%	20.3%	13.0%
Adjusted EPS (₹)	-5.3	-5.5	-1.9	-0.5	1.8	-0.2	3.6	1.9	1.4	0.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Zenotech Laboratorie - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	-46	-66	42	39	50	48	71	82	91	96
Share Capital ⓘ	34	34	61	61	61	61	61	61	61	61
Reserves ⓘ	-80	-100	-19	-22	-11	-13	10	21	30	35
Debt +	51	51	0	20	19	21	6	0	0	0
Long Term Debt	0	0	0	0	0	21	6	0	0	0
Short Term Debt	51	51	0	20	19	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	5	5	4	5	2	2	3	3	3
Others Liabilities ⓘ	44	60	34	21	13	15	3	6	6	8
Total Liabilities ⓘ	53	51	82	85	86	86	82	92	100	107
Fixed Assets
Net Fixed Assets ⓘ +	48	47	44	43	49	74	71	65	66	61
Gross Block	52	55	56	59	70	101	105	107	114	116
Accumulated Depreciation	4	8	12	16	21	27	34	41	48	55
CWIP ⓘ	0	0	2	17	29	2	0	5	2	4
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	2	1	1	1	0	0	0	0	1	0
Trade Receivables	0	0	0	2	2	4	4	3	3	7
Cash Equivalents ⓘ	0	1	29	13	1	2	2	11	20	27
Others Assets ⓘ	2	2	5	8	5	3	4	7	8	8
Total Assets ⓘ	53	51	82	85	86	86	82	92	100	107

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-5	2	-16	-14	11	6	18	21	12	9
PBT ⓘ	-19	-20	-12	-3	11	-1	10	15	11	11
Adjustment ⓘ	12	10	5	-0	-2	8	8	7	6	4
Changes in Working Capital ⓘ	2	12	-9	-10	3	-1	1	0	-4	-3
Tax Paid ⓘ	1	0	-0	-0	-0	-0	-1	-1	-1	-2
Cash Flow From Investing Activity ⓘ +	5	-1	-3	-16	-21	-5	-2	-6	-21	15
Capex	-0	-1	-4	-18	-22	-5	-2	-6	-4	-4
Net Investments	5	0	-1	1	0	0	0	0	0	0
Others ⓘ	0	0	2	1	1	0	0	0	-17	19
Cash Flow From Financing Activity ⓘ +	-1	-1	47	15	-3	0	-16	-6	0	0
Net Proceeds from Shares ⓘ	-0	0	120	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-0	-0	-3	0	-12	0	-15	-6	0	0
Interest Paid ⓘ	-1	-1	-19	-5	-1	-2	-1	-0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	-51	20	10	2	0	0	0	0
Net Cash Flow ⓘ	-0	0	28	-15	-12	1	-0	9	-9	25

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	N/A	N/A	0	-7.73	24.35	-2.48	37.26	15.15	9.6	6.01
ROCE (%)	N/A	N/A	-61.88	-5.95	18.32	0.48	15.26	18.39	12.89	11.46
Asset Turnover Ratio	0.04	0.04	0.17	0.16	0.31	0.26	0.44	0.49	0.43	0.42
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	1	N/A	0.82	1.75	1.5	1.5
Working Capital Days
Receivable Days	62	28.20	0.10	33.10	29.60	46	38.60	31.20	29.40	45.40
Inventory Days	302.40	203.10	28.60	19.70	4.80	1.30	0.60	0	7.50	0
Payable Days	594.10	1,026.30	2,410	2,424	3,153.50	0	0	0	0	1,263.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Zenotech Laboratories Ltd FAQs

The current trading price of Zenotech Laboratorie on 04-Jun-2026 16:59 is ₹45.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Zenotech Laboratorie stood at ₹274.6 Cr

The latest P/E ratio of Zenotech Laboratorie as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Zenotech Laboratorie as of 03-Jun-2026 is 2.89.

The 52-week high of Zenotech Laboratorie is ₹67.00 and the 52-week low is ₹33.55.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zenotech Laboratorie is ₹39.56 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Zenotech Laboratories Ltd is a average quality company.

The key valuation ratios of Zenotech Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenotech Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.

Zenotechâ€™s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.

Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.

Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.

Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.

Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.

Product range of the company includes:

Generics -- Biological

Nugraf
Macrogen

Chemical

Gemcitabine for Injection
Paclitaxel for Injection
Docetaxel for Injection
Irinotecan for Injection
Oxaliplatin for Injection
Epirubicin for Injection
Bleomycin for Injection
Cisplatin for Injection
Carboplatin for Injection
Ifosfamide for Injection
Etoposide for Injection

New biologicals Zenotech develops new biological entities in the areas of

Cancer
Neurology

Zenotech Laboratories Ltd (532039)

Zenotech Laboratories Ltd (532039)

Zenotech Laboratories stock performance